The US Food and Drug Administration (FDA) has approved Fujirebio Diagnostics’ Alzheimer’s disease (AD) blood test to help ...

The US Food and Drug Administration (FDA) has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA's clearance of the first blood test to diagnose ...

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal brain function.

The very first blood test for Alzheimer's disease detection has been green-lit by the US Food and Drug Administration (FDA), ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the ...

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

The FDA has granted 510(k) marketing clearance to the first in vitro blood-based biomarker diagnostic device for Alzheimer’s ...

Experts say the test could dramatically improve access to earlier, more accurate diagnoses, particularly for older Americans ...

Since Alzheimer's disease affects over 7 million people in the U.S., potentially doubling to 14 million by 2050, earlier ...